Floatz logo

Fludarabine

Diffuse Large B-cell Lymphoma (DLBCL)

AvenCell Therapeutics, Inc.Small moleculePhase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
81/ 100

Competitive context

270 Active assets in the Diffuse Large B-cell Lymphoma (DLBCL) cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
FILGRASTIM
Ruijin Hospital
Phase 3BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Fludarabine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi anemiaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Adult Diffuse Large Cell LymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →